CN115297892A - 抗新型冠状病毒感染的mRNA疫苗的组合物和方法 - Google Patents

抗新型冠状病毒感染的mRNA疫苗的组合物和方法 Download PDF

Info

Publication number
CN115297892A
CN115297892A CN202180024212.1A CN202180024212A CN115297892A CN 115297892 A CN115297892 A CN 115297892A CN 202180024212 A CN202180024212 A CN 202180024212A CN 115297892 A CN115297892 A CN 115297892A
Authority
CN
China
Prior art keywords
mrna
composition
orf
seq
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180024212.1A
Other languages
English (en)
Chinese (zh)
Inventor
唐盛高
沈栋
陆春
何耔阳
何嘉熙
帕特里克·Y·陆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Damian Biology Co ltd
Original Assignee
Damian Biology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Damian Biology Co ltd filed Critical Damian Biology Co ltd
Publication of CN115297892A publication Critical patent/CN115297892A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
CN202180024212.1A 2020-02-07 2021-02-08 抗新型冠状病毒感染的mRNA疫苗的组合物和方法 Pending CN115297892A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062971834P 2020-02-07 2020-02-07
US62/971,834 2020-02-07
US202063058463P 2020-07-29 2020-07-29
US63/058,463 2020-07-29
US202063130581P 2020-12-24 2020-12-24
US63/130,581 2020-12-24
PCT/US2021/017149 WO2021159118A2 (en) 2020-02-07 2021-02-08 Composition and method of mrna vaccines against novel coronavirus infection

Publications (1)

Publication Number Publication Date
CN115297892A true CN115297892A (zh) 2022-11-04

Family

ID=77200778

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180024212.1A Pending CN115297892A (zh) 2020-02-07 2021-02-08 抗新型冠状病毒感染的mRNA疫苗的组合物和方法

Country Status (11)

Country Link
US (2) US12029786B2 (https=)
EP (1) EP4100066A4 (https=)
JP (1) JP2023512833A (https=)
KR (1) KR20220143684A (https=)
CN (1) CN115297892A (https=)
AU (1) AU2021216443A1 (https=)
BR (1) BR112022015626A2 (https=)
CA (1) CA3167257A1 (https=)
IL (1) IL295360A (https=)
MX (1) MX2022009688A (https=)
WO (1) WO2021159118A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12029786B2 (en) 2020-02-07 2024-07-09 RNAimmune, Inc. Composition and method of mRNA vaccines against novel coronavirus infection
WO2021160887A1 (en) * 2020-02-14 2021-08-19 Immunor As Corona virus vaccine
JPWO2021181994A1 (https=) * 2020-03-10 2021-09-16
US20230313323A1 (en) * 2020-03-26 2023-10-05 Ionian Technologies, Llc Assays for detecting coronavirus disease 2019 (covid-19)
IL297419B2 (en) 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
EP4334479A4 (en) * 2021-05-06 2025-02-19 Lu, Shi-Long DETECTION OF VIRAL VARIANTS
JP2024530672A (ja) 2021-08-11 2024-08-23 アールエヌエーイミューン、インコーポレイテッド 新規なコロナウイルス感染症に対するｍＲＮＡワクチンの組成物および方法
WO2023020939A1 (en) * 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
CN118475371A (zh) * 2021-09-22 2024-08-09 圣诺制药公司 基于组氨酸-赖氨酸共聚物形成的改善的纳米颗粒制剂
WO2023049814A2 (en) * 2021-09-22 2023-03-30 Sirnaomics, Inc. Nanoparticle pharmaceutical compositions with reduced nanoparticle size and improved polydispersity index
CN113881806A (zh) * 2021-09-23 2022-01-04 华南理工大学 基于CRISPR/Cas12a技术检测新冠病毒和69/70突变株的方法及试剂盒
EP4183409A1 (en) * 2021-11-17 2023-05-24 Charité - Universitätsmedizin Berlin Vaccine with improved immunogenicity against mutant coronaviruses
WO2023091766A2 (en) * 2021-11-19 2023-05-25 RNAimmune, Inc. Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines
AU2022398292A1 (en) * 2021-11-29 2024-06-13 BioNTech SE Coronavirus vaccine
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
CN118556131A (zh) 2022-01-27 2024-08-27 爱思开生物科技有限公司 用于蛋白质表达的mRNA及其模板
US20250228929A1 (en) * 2022-04-03 2025-07-17 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant
US20240207389A1 (en) * 2022-04-27 2024-06-27 Northwestern University Methods for improving covid vaccine immunogenicity
DE102023002588A1 (de) * 2022-06-26 2024-01-25 BioNTech SE Coronavirus-Impfstoff
WO2024002985A1 (en) * 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
US12280104B2 (en) 2022-11-01 2025-04-22 RNAimmune, Inc. Composition and methods for MRNA vaccines against novel omicron coronavirus infections
KR102832944B1 (ko) * 2024-12-27 2025-07-15 대한민국 제2형 중증급성호흡기증후군 코로나바이러스 변이들의 공통 서열을 포함하는 코로나바이러스감염증-19 범용 백신 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190240317A1 (en) * 2015-10-22 2019-08-08 Modernatx, Inc. Hpiv3 rna vaccines
US20190351048A1 (en) * 2016-12-23 2019-11-21 Curevac Ag Mers coronavirus vaccine
CN110520155A (zh) * 2017-02-28 2019-11-29 广州纳泰生物医药技术有限公司 预防和治疗寨卡病毒感染的rna药物制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1270732A1 (en) * 2001-06-21 2003-01-02 Schuler, Gerold Improved transfection of eukaryontic cells with linear polynucleotides by electroporation
DE102005046490A1 (de) * 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
SG11201405542UA (en) * 2012-03-27 2014-10-30 Curevac Gmbh Artificial nucleic acid molecules
AU2019275071B2 (en) * 2018-05-24 2022-12-15 Sirnaomics, Inc. Composition and methods of controllable co-coupling polypeptide nanoparticle delivery system for nucleic acid therapeutics
PH12022551788A1 (en) * 2020-01-28 2024-02-26 Codagenix Inc DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOF
JP2023512519A (ja) 2020-01-31 2023-03-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン
US12029786B2 (en) 2020-02-07 2024-07-09 RNAimmune, Inc. Composition and method of mRNA vaccines against novel coronavirus infection
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
US20210316002A1 (en) 2020-04-14 2021-10-14 Ut-Battelle, Llc Compositions and methods for drug delivery and treating viral infections
BR112022024662A2 (pt) 2020-06-03 2023-04-04 Regeneron Pharma Métodos para tratamento ou prevenção de infecções por sars-cov-2 e covid-19 com anticorpos de glicoproteína spike anti-sars-cov-2
EP4204015A4 (en) 2020-08-31 2025-01-01 The Board of Trustees of the Leland Stanford Junior University Systems and methods for producing rna constructs with increased translation and stability
US20250213679A1 (en) 2020-10-02 2025-07-03 Celsion Corporation Polynucleotide vaccines and methods of using the same
CN115160413B (zh) 2021-04-06 2023-11-14 清华大学 一种新型冠状病毒疫苗

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190240317A1 (en) * 2015-10-22 2019-08-08 Modernatx, Inc. Hpiv3 rna vaccines
US20190351048A1 (en) * 2016-12-23 2019-11-21 Curevac Ag Mers coronavirus vaccine
CN110520155A (zh) * 2017-02-28 2019-11-29 广州纳泰生物医药技术有限公司 预防和治疗寨卡病毒感染的rna药物制剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JIAXI HE ET AL.: "Location of a single histidine within peptide carriers increases mRNA delivery", J GENE MED., vol. 23, no. 2, 21 December 2020 (2020-12-21), pages 1 - 11 *
LENG ET AL.: "Histidine-Lysine Peptides as Carriers of Nucleic Acids", DRUG NEWS PERSPECT, vol. 20, no. 2, 31 March 2007 (2007-03-31), pages 77 - 86, XP001526414, DOI: 10.1358/dnp.2007.20.2.1083026 *
LU ET AL.: "Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding", LANCET, 29 January 2020 (2020-01-29) *

Also Published As

Publication number Publication date
WO2021159118A3 (en) 2021-10-28
IL295360A (en) 2022-10-01
EP4100066A4 (en) 2024-05-01
JP2023512833A (ja) 2023-03-29
KR20220143684A (ko) 2022-10-25
CA3167257A1 (en) 2021-08-12
US12029786B2 (en) 2024-07-09
WO2021159118A2 (en) 2021-08-12
MX2022009688A (es) 2022-12-15
US20230108926A1 (en) 2023-04-06
US20220040292A1 (en) 2022-02-10
EP4100066A2 (en) 2022-12-14
BR112022015626A2 (pt) 2022-10-11
AU2021216443A1 (en) 2022-09-08
WO2021159118A8 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
US12029786B2 (en) Composition and method of mRNA vaccines against novel coronavirus infection
US20240294580A1 (en) Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines
CN118119930A (zh) 抗新型冠状病毒感染的mRNA疫苗的组合物和方法
EP4059515A1 (en) Nucleic acid lipid particle vaccine encapsulating hpv mrna
CN116917470A (zh) PAN-RAS mRNA癌症疫苗
WO2023051701A1 (zh) 抗SARS-CoV-2感染的mRNA、蛋白以及抗SARS-CoV-2感染的疫苗
US12280104B2 (en) Composition and methods for MRNA vaccines against novel omicron coronavirus infections
CN117205309B (zh) 一种流感免疫原组合物和制备方法及其用途
CN116426543B (zh) 一种新型冠状病毒疫苗及其制备方法
WO2024234756A1 (zh) 针对猫FIPV的M和N抗原构建mRNA和疫苗的方法
CA3130956A1 (en) Novel vaccine effective to prevent infection by sars-cov variants
US20260041759A1 (en) COVID19 mRNA Vaccine
WO2025024336A1 (en) Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines
CN117683790A (zh) 一种嗜肺军团菌相关抗原的mRNA疫苗及其制备方法与用途
WO2025075129A1 (ja) コロナウイルススパイクタンパク質変異体
WO2024234755A1 (zh) 针对猫FIPV的多抗原mRNA疫苗开发
CN116042656A (zh) 一种猴痘病毒mRNA疫苗及其制备方法与用途
WO2024234754A1 (zh) 针对猫fipv构建环状rna和疫苗的方法
WO2026071160A1 (ja) Ｂ型肝炎ウイルスに対する免疫原性組成物
CN119497628A (zh) 一种抵抗呼吸道合胞病毒的mRNA疫苗及其制备方法
HK40074627A (en) Nucleic acid lipid particle vaccine encapsulating hpv mrna

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Tang Shenggao

Inventor after: Shen Dong

Inventor after: Lu Chun

Inventor after: He Ziyang

Inventor after: He Jiaxi

Inventor after: Patrick Y. Lu

Inventor before: Tang Shenggao

Inventor before: Shen Dong

Inventor before: Lu Chun

Inventor before: He Ziyang

Inventor before: He Jiaxi

Inventor before: Patrick Y. Lu

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination